We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Bill Crossman is the President & CEO of Phoenix PharmaLabs, INC. (PPL), a pre-clinical drug discovery company. PPL has developed a safe, potent (10x stronger than morphine), non-addicting opioid analgesic that offers a promising solution to the massive opioid addiction problem. The drug has also demonstrated potential as an improved opioid addiction therapy drug and is currently being studied for applications in other therapeutic areas as well.
For the past 20 years Bill has been launching early stage technology companies in industries ranging from life sciences to nanotechnology, software development and industrial technologies. He is a senior management professional with international and domestic experience as CEO, COO and CFO of enterprises ranging from entrepreneurial start-ups to Fortune 500 level companies.
Bill holds a BS degree from the US Merchant Marine Academy and an MBA from UC –Berkeley.
This speaker's sessions: